Drug class
Muscarinic Antagonists clinical trials
A class of medicines: the studies that test any of its 41 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones.
Keep track of what changes. Save the muscarinic antagonists studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesMedicines in this class
Studies that test each. A study of two counts under both, and once above.
- Hyoscyamine
- 2
- Propantheline
- 2
- LAS190792
- 1
- Telenzepine
- 1
- Octylonium
- 1
- Tarafenacin
- 1
- Methantheline
- 1
- Drotaverine hydrochloride
- 1
- Flavoxate
- 1
And 1 more, each tested in fewer studies.
Studies by the year they started
1,066 studies that test it; most in 2012 (65); 1 more planned to start later
| Year | Studies |
|---|---|
| 1995 | 1 |
| 1996 | 1 |
| 1998 | 6 |
| 1999 | 6 |
| 2000 | 4 |
| 2001 | 5 |
| 2002 | 26 |
| 2003 | 15 |
| 2004 | 23 |
| 2005 | 23 |
| 2006 | 40 |
| 2007 | 56 |
| 2008 | 49 |
| 2009 | 62 |
| 2010 | 55 |
| 2011 | 52 |
| 2012 | 65 |
| 2013 | 50 |
| 2014 | 53 |
| 2015 | 51 |
| 2016 | 58 |
| 2017 | 42 |
| 2018 | 42 |
| 2019 | 37 |
| 2020 | 28 |
| 2021 | 35 |
| 2022 | 44 |
| 2023 | 41 |
| 2024 | 30 |
| 2025 | 35 |
| 2026 | 31 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 580 · Other 490
Boehringer Ingelheim (98) · GlaxoSmithKline (67) · AstraZeneca (39) · Pfizer (34) · Novartis Pharmaceuticals (30) · Astellas Pharma Inc (28) · Pearl Therapeutics, Inc. (19) · Bristol-Myers Squibb (18)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten.
Testing one of them · 1,070
- A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)RecruitingPhase 3Bristol-Myers SquibbNCT06929273Written as KarXT
- A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia ControlRecruitingPhase 3Jaeb Center for Health ResearchNCT07095894Written as Atropine
- Conscious Sedation Versus General Anesthesia for Pulsed Field Ablation in Paroxysmal Atrial FibrillationRecruitingNot applicableChina National Center for Cardiovascular DiseasesNCT07877519Written as Atropine
- A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I DisorderRecruitingPhase 3Bristol-Myers SquibbNCT06951698Written as KarXT
- A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)RecruitingPhase 3Bristol-Myers SquibbNCT06951711Written as KarXT
- Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD)Not yet recruitingPhase 4University of Tennessee Graduate School of MedicineNCT07721922Written as Revefenacin
- Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting BronchodilatorsRecruitingPhase 4University of Tennessee Graduate School of MedicineNCT07133880Written as umeclidinium 62.5 µg and vilanterol 25 µg
- A Study to Evaluate the Effect of KarXT on Urological SafetyRecruitingPhase 4Bristol-Myers SquibbNCT07221877Written as Xanomeline/trospium chloride
- A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)RecruitingPhase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT06126224Written as KarXT
- Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)RecruitingPhase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT05980949Written as KarXT
- A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)RecruitingPhase 3Bristol-Myers SquibbNCT06937229Written as KarXT
- A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)RecruitingPhase 3Bristol-Myers SquibbNCT07011732Written as Xanomeline/Trospium Chloride Capsule
- Low-Dose Atropine Eye Drops for Excessive Tearing (Epiphora)RecruitingPhase 2Rehan AhmedNCT07816224Written as Atropine sulfate ophthalmic solution 0.005%
- A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult ParticipantsRecruitingPhase 1Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT07204418Written as Xanomeline/ Trospium Chloride
- A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALSRecruitingPhase 2Oliver BlanchardNCT06249867Written as Darifenacin 7.5 MG Extended Release Oral Tablet
- A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)RecruitingPhase 3Bristol-Myers SquibbNCT06976203Written as KarXT
- A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's DiseaseRecruitingPhase 3Bristol-Myers SquibbNCT07011745Written as Xanomeline/Trospium Chloride Capsule
- Early Intervention for High Risk Premyopic ChildrenNot yet recruitingPhase 2National Yang Ming Chiao Tung University HospitalNCT07863713Written as 0.025% atropine eye drops
- A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseaseRecruitingPhase 3Bristol-Myers SquibbNCT06976216Written as KarXT
- A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)RecruitingPhase 3Bristol-Myers SquibbNCT07288567Written as KarXT
See all 1,070 studies that test one of the muscarinic antagonists →
Codes
What other systems call Muscarinic Antagonists · ClinicalTrials.gg INT008648
- MeSH (NLM) D018727Muscarinic AntagonistsOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D018727 | Muscarinic Antagonists | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.